Amicus Therapeutics (NASDAQ: FOLD): Reiterating Buy Rating With Price Target=$10 Ahead Of Upcoming Catalysts

FOLD

We initiated coverage on Amicus Therapeutics (FOLD) in early December, 2016. Phase 3 results of SD-101 in the treatment of epidermolysis bullosa, EB are expected in mid-2017. In addition, the company has made more progress in commercializing migalastat for the treatment of Fabry's disease (with a...

We initiated coverage on Amicus Therapeutics (FOLD) in early December, 2016. Phase 3 results of SD-101 in the treatment of epidermolysis bullosa, EB are expected in mid-2017. In addition, the company has made more progress in commercializing migalastat for the treatment of Fabry's disease (with a...

This article is only available to subscribers of Vasuda Healthcare Analytics
Learn more about Vasuda Healthcare Analytics